The European Commission conducted surprise raids of several pharmaceutical companies, including Lundbeck A/S as part of the investigation into suspected anti-competitive practices. In raiding the companies, EC had reason to believe that prohibitions on restrictive business practices or the abuse of a dominant position may have been infringed.